Legal Action Underway: PROCEPT BioRobotics Faces Class Action Lawsuit Amid Allegations of Misleading Sales Practices

PROCEPT BioRobotics Faces Legal Challenge Over Alleged Sales Misconduct

Investors are encouraged to take notice as Hagens Berman Sobol Shapiro LLP sheds light on a securities class action lawsuit initiated against PROCEPT BioRobotics Corporation (NASDAQ: PRCT). The action stems from serious allegations regarding the company’s sales practices connected to its Aquablation therapy, designed for treating enlarged prostates. Investors who acquired PROCEPT shares from February 28, 2024, to February 25, 2026, may be eligible to participate in this lawsuit, especially those who have incurred substantial financial losses.

Background of the Allegations

According to the law firm, the lawsuit comes after PROCEPT's unexpected underperformance in unit handpiece sales and the uncovering of excessive customer inventory levels. Investors are suggesting that the company used an aggressive discount strategy to incentivize bulk sales, which didn’t align with customer demand. This approach ultimately distorted the company’s reported sales figures, misleading investors about the health and viability of its business operations.

The lawsuit points towards a troubling pattern of misleading information conveyed to investors throughout this period. It outlines concerns that PROCEPT outlined growth in sales while concealing significant inventory issues and improper management of customer purchases. This led to inflated stock prices that later fell dramatically when corrective disclosures were finally made.

Timeline of Events and Impact on Shareholders

The problems became increasingly visible starting with the company's announcement on August 6, 2025. During its second-quarter earnings call, PROCEPT reported disappointing handpiece sales performance, falling short of consensus estimates, triggering alarm among investors. Following that, on November 4, 2025, the company again revealed a failure to meet expected sales figures, this time adjusting its forecast for annual handpiece sales downwards. Management acknowledged the prevalence of excess inventory among customers, hinting at a significant operational misjudgment.

Finally, on February 25, 2026, a comprehensive uncovering of the situation occurred when PROCEPT disclosed critical information about the actual use of the handpieces. This revelation indicated that sales had far exceeded the number of procedures performed, resulting in over 10,000 units of excess inventory. The revelation led to a drastic decline in share prices by over 48% since the troubling financial results were first announced.

Next Steps for Affected Investors

The investigation led by Hagens Berman seeks to establish whether there was intentional misconduct on PROCEPT's part in the reporting of its sales and inventory practices. Reed Kathrein, a partner at the firm, stressed that the focus remains on the transparency of PROCEPT's communications with its investors.

Investors who find themselves facing considerable losses are urged to consider taking part in the ongoing class action and to provide any information that might aid in the investigation's progress. Individuals with knowledge about the internal workings of PROCEPT during the pertinent time are invited to engage with the law firm and help illuminate the situation further.

Potential plaintiffs are reminded that the deadline for leading the class action lawsuit is set for September 22, 2026. Interested parties can find more details and initiate their participation by visiting Hagens Berman’s official website or reaching out to their legal team directly.

Conclusion

This class action lawsuit marks a significant moment for PROCEPT BioRobotics Corporation and its investors. With allegations of misleading sales practices and potential violations of securities laws, the outcome will not only impact the company but also underline the importance of transparency in investor communications. As investigations unfold, industry watchers will closely monitor how the situation progresses and what it means for the future of PROCEPT and its affiliates.